NORA520 / Gerbera Therap - LARVOL DELTA

NuMom: A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression (clinicaltrials.gov) - P2 | N=93 | Completed | Sponsor: DuKang Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry

NuMom: A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: DuKang Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry

NuMom: A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: DuKang Pharmaceuticals, Inc. | Trial completion date: Mar 2026 ➔ Dec 2025 | Trial primary completion date: Feb 2026 ➔ Nov 2025

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry

NuMom: A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Gerbera Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry

NuMom: A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Gerbera Therapeutics, Inc.

New P2 trial • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry